Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
复制标题
DOI：
10.1245/s10434-015-4934-0
复制
发表时间：
2016-04
影响因子：
3.7
通讯作者：
Hirakawa K
中科院分区：
文献类型：
--
作者：
Asano Y;Kashiwagi S;Onoda N;Noda S;Kawajiri H;Takashima T;Ohsawa M;Kitagawa S;Hirakawa K
据报道，中性粒细胞/淋巴细胞比率(NLR)通过影响肿瘤进展和化疗敏感性而与癌症患者的预后有关。然而，NLR与乳腺癌患者新辅助化疗(NAC)结果的相关性仍不清楚。177例乳腺癌患者接受NAC联合5-氟尿嘧啶、表阿霉素和环磷酰胺治疗，然后每周接受紫杉醇治疗和随后的根治性手术。回顾分析NLR与预后的关系，包括NAC的疗效。NLR在0.5至10.6之间。与高NLR值(≥3.0)相比，低NLR值患者的病理完全缓解率(P<0.001)和ER/PR阴性/HER2阴性(三阴性)乳腺癌的发生率(P<0.001)显著高于高NLR值患者(P<0.05)。在获得聚合酶链式反应的TNBC患者中，NLR低的患者的无病生存期(p=0.006)和总生存期(p<0.001)显著长于NLR高的患者。根据单因素分析，在获得聚合酶链式反应的TNBC患者中，较低的NLR值与显著的良好预后相关(p=0.044，风险比t=0.06)。NLR的降低可能预示着TNBC患者NAC后的疗效和预后良好。本文的在线版本(doi：10.1245/s10434-0154934-0)包含补充材料，授权用户可以使用。
The neutrophil/lymphocyte ratio (NLR) has been reportedly associated with prognosis in cancer patients by influencing both cancer progression and chemosensitivity. However, the correlation between NLR and the outcome of neoadjuvant chemotherapy (NAC) in breast cancer patients remains unclear. NLR was evaluated in 177 patients with breast cancer treated with NAC with 5-fluorouracil, epirubicin, and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery. The correlation between NLR and prognosis, including the efficacy of NAC, was evaluated retrospectively. NLR ranged from 0.5 to 10.6. Fifty-eight patients with low NLR (<3.0) had a higher pathological complete response (pCR) rate (p < 0.001) and were more frequently diagnosed with ER-negative/progesterone receptor (PR)-negative/HER2-negative (triple-negative) breast cancer (TNBC; p < 0.001) compared with patients with high NLR (≥3.0). Among TNBC patients who achieved pCR, disease-free survival (p = 0.006) and overall survival (p < 0.001) were significantly longer in patients with low NLR than in those with high NLR. Low NLR was associated with a significantly favorable prognosis in TNBC patients who achieved pCR, according to univariate analysis (p = 0.044, hazard ratio = 0.06). Low NLR may indicate high efficacy and favorable outcome after NAC in patients with TNBC. The online version of this article (doi:10.1245/s10434-015-4934-0) contains supplementary material, which is available to authorized users.